Akela Pharma, Inc

We are an integrated product development company primarily focused on therapeutics for pain utilizing our proprietary drug delivery technologies. Our lead product candidate is Fentanyl TAIFUN, a fentanyl formulation specifically designed to be delivered with our TAIFUN Multi-Dose Inhaler. We are developingFentanyl TAIFUN as a rapid-acting inhaled opioid analgesic for treatment of break-through cancer pain. In June 2007, we entered into an exclusive license and development agreement with Janssen Pharmaceutica N.V. with respect to the continuing development and commercialization of Fentanyl TAIFUN. We believe, based upon the results of our clinical trials to date, that our Fentanyl TAIFUN product candidate, if approved by regulatory agencies, will deliver much faster onset of pain relief from break-through cancer pain at lower dosages than other non-injectable products currently indicated for break-through cancer pain. Break-through cancer-related pain has a severe impact on a ...